Amendment: SEC Form SC 13G/A filed by Spyre Therapeutics Inc.

11/14/24 5:50:33 PM ET

$SYRE

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SYRE alert in real time by email

SC 13G/A 1 tm2428137d15_sc13ga.htm SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Spyre Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 Par Value Per Share

(Title of Class of Securities)

00773J202

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 00773J202

Page 2 of 14

1.	Names of Reporting Persons Venrock Healthcare Capital Partners III, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only

4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 2,685,448 (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 2,685,448 (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,685,448 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

11.	Percent of Class Represented by Amount in Row (9) 5.3% (3)
12.	Type of Reporting Person (See Instructions) PN

(1)

Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

(2)

Consists of (i) 324,917 shares of common stock held by Venrock Healthcare Capital Partners III, L.P.; (ii) 32,505 shares of common stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,328,026 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P.

(3)

This percentage is calculated based upon 50,792,374 shares of common stock outstanding as of August 1, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 7, 2024.

CUSIP No. 00773J202

Page 3 of 14

1.	Names of Reporting Persons VHCP Co-Investment Holdings III, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only

4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 2,685,448 (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 2,685,448 (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,685,448 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

11.	Percent of Class Represented by Amount in Row (9) 5.3% (3)
12.	Type of Reporting Person (See Instructions) OO

(1)

(2)

(3)

CUSIP No. 00773J202

Page 4 of 14

1.	Names of Reporting Persons Venrock Healthcare Capital Partners EG, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only

4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 2,685,448 (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 2,685,448 (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,685,448 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

11.	Percent of Class Represented by Amount in Row (9) 5.3% (3)
12.	Type of Reporting Person (See Instructions) PN

(1)

(2)

(3)

CUSIP No. 00773J202

Page 5 of 14

1.	Names of Reporting Persons VHCP Management III, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 2,685,448 (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 2,685,448 (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,685,448 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row (9) 5.3% (3)
12.	Type of Reporting Person (See Instructions) OO

(1)

(2)

(3)

CUSIP No. 00773J202

Page 6 of 14

1.	Names of Reporting Persons VHCP Management EG, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 2,685,448 (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 2,685,448 (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,685,448 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 5.3% (3)
12.	Type of Reporting Person (See Instructions) OO

(1)

(2)

(3)

CUSIP No. 00773J202

Page 7 of 14

1.	Names of Reporting Persons Shah, Nimish
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☒ (1) (b) ☐
3.	SEC Use Only
4.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 2,685,448 (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 2,685,448 (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,685,448 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
11.	Percent of Class Represented by Amount in Row (9) 5.3% (3)
12.	Type of Reporting Person (See Instructions) IN

(1)

(2)

(3)

CUSIP No. 00773J202

Page 8 of 14

1.	Names of Reporting Persons Koh, Bong
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 2,685,448 (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 2,685,448 (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 2,685,448 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 5.3% (3)
12.	Type of Reporting Person (See Instructions) IN

(1)

(2)

(3)

CUSIP No. 00773J202

Page 9 of 14

Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP III LP, VHCP Co-Investment III, VHCP EG and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of the Common Stock of Spyre Therapeutics, Inc.

Item 1.
	(a)	Name of Issuer Spyre Therapeutics, Inc.

	(b)	Address of Issuer’s Principal Executive Offices 221 Crescent Street Building 23, Suite 105 Waltham, MA 02453

Item 2.
	(a)	Name of Person Filing Venrock Healthcare Capital Partners III, L.P. VHCP Co-Investment Holdings III, LLC Venrock Healthcare Capital Partners EG, L.P. VHCP Management III, LLC VHCP Management EG, LLC Nimish Shah Bong Koh

	(b)	Address of Principal Business Office or, if none, Residence

		New York Office:	Palo Alto Office:

		7 Bryant Park	3340 Hillview Avenue
		23rd Floor	Palo Alto, CA 94304
		New York, NY 10018
	(c)	Citizenship All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

	(d)	Title of Class of Securities Common Stock, $0.0001 par value per share

	(e)	CUSIP Number 00773J202

CUSIP No. 00773J202

Page 10 of 14

Item 3.	If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

	Not applicable

Item 4.

Ownership

(a)

Amount beneficially owned as of September 30, 2024:

Venrock Healthcare Capital Partners III, L.P.	2,685,448	(1)
VHCP Co-Investment Holdings III, LLC	2,685,448	(1)
Venrock Healthcare Capital Partners EG, L.P.	2,685,448	(1)
VHCP Management III, LLC	2,685,448	(1)
VHCP Management EG, LLC	2,685,448	(1)
Nimish Shah	2,685,448	(1)
Bong Koh	2,685,448	(1)

(b)

Percent of class as of September 30, 2024:

Venrock Healthcare Capital Partners III, L.P.	5.3%	(2)
VHCP Co-Investment Holdings III, LLC	5.3%	(2)
Venrock Healthcare Capital Partners EG, L.P.	5.3%	(2)
VHCP Management III, LLC	5.3%	(2)
VHCP Management EG, LLC	5.3%	(2)
Nimish Shah	5.3%	(2)
Bong Koh	5.3%	(2)

(c)	Number of shares as to which the person has, as of September 30, 2024:

	(i)	Sole power to vote or to direct the vote:

Venrock Healthcare Capital Partners III, L.P.			0
VHCP Co-Investment Holdings III, LLC			0
Venrock Healthcare Capital Partners EG, L.P.			0
VHCP Management III, LLC			0
VHCP Management EG, LLC			0
Nimish Shah			0
Bong Koh			0

CUSIP No. 00773J202

Page 11 of 14

(ii)

Shared power to vote or to direct the vote:

Venrock Healthcare Capital Partners III, L.P.	2,685,448	(1)
VHCP Co-Investment Holdings III, LLC	2,685,448	(1)
Venrock Healthcare Capital Partners EG, L.P.	2,685,448	(1)
VHCP Management III, LLC	2,685,448	(1)
VHCP Management EG, LLC	2,685,448	(1)
Nimish Shah	2,685,448	(1)
Bong Koh	2,685,448	(1)

(iii)

Sole power to dispose or to direct the disposition of:

Venrock Healthcare Capital Partners III, L.P.			0
VHCP Co-Investment Holdings III, LLC			0
Venrock Healthcare Capital Partners EG, L.P.			0
VHCP Management III, LLC			0
VHCP Management EG, LLC			0
Nimish Shah			0
Bong Koh			0

(iv)

Shared power to dispose or to direct the disposition of:

Venrock Healthcare Capital Partners III, L.P.	2,685,448	(1)
VHCP Co-Investment Holdings III, LLC	2,685,448	(1)
Venrock Healthcare Capital Partners EG, L.P.	2,685,448	(1)
VHCP Management III, LLC	2,685,448	(1)
VHCP Management EG, LLC	2,685,448	(1)
Nimish Shah	2,685,448	(1)
Bong Koh	2,685,448	(1)

	(1)	Consists of (i) 324,917 shares of common stock held by Venrock Healthcare Capital Partners III, L.P.; (ii) 32,505 shares of common stock held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,328,026 shares of common stock held by Venrock Healthcare Capital Partners EG, L.P.

		VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

	(2)	This percentage is calculated based upon 50,792,374 shares of common stock outstanding as of August 1, 2024 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024.

Item 5.	Ownership of Five Percent or Less of a Class

	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐

CUSIP No. 00773J202

Page 12 of 14

Item 6.	Ownership of More than Five Percent on Behalf of Another Person

	Not applicable

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

	Not applicable

Item 8.	Identification and Classification of Members of the Group

	Not applicable

Item 9.	Notice of Dissolution of Group

	Not applicable

Item 10.	Certification

	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

CUSIP No. 00773J202

Page 13 of 14

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 14, 2024

Venrock Healthcare Capital Partners III, L.P.		Venrock Healthcare Capital Partners EG, L.P.

By:	VHCP Management III, LLC	By:	VHCP Management EG, LLC
Its:	General Partner	Its:	General Partner

By:	/s/ Sherman G. Souther	By:	/s/ Sherman G. Souther
	Name: Sherman G. Souther		Name: Sherman G. Souther
	Its: Authorized Signatory		Its: Authorized Signatory

VHCP Co-Investment Holdings III, LLC

By:	VHCP Management III, LLC
Its:	Manager

By:	/s/ Sherman G. Souther
	Name: Sherman G. Souther
	Its: Authorized Signatory

VHCP Management III, LLC		VHCP Management EG, LLC

By:	/s/ Sherman G. Souther	By:	/s/ Sherman G. Souther
	Name: Sherman G. Souther		Name: Sherman G. Souther
	Its: Authorized Signatory		Its: Authorized Signatory

Nimish Shah

/s/ Sherman G. Souther
Sherman G. Souther, Attorney-in-fact

Bong Koh

/s/ Sherman G. Souther
Sherman G. Souther, Attorney-in-fact

CUSIP No. 00773J202

Page 14 of 14

EXHIBITS

Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on July 10, 2023)

Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed July 10, 2023)

Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on July 10, 2023)

Get the next $SYRE alert in real time by email

Date	Price Target	Rating	Analyst
9/4/2024	$45.00	Outperform	Wedbush
7/16/2024		Outperform	Evercore ISI
5/2/2024	$50.00	Outperform	Robert W. Baird
3/1/2024	$12.00 → $35.00	Equal Weight → Overweight	Wells Fargo

Amendment: SEC Form SC 13G/A filed by Spyre Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for $SYRE

$SYRE Press Releases

Fastest customizable press release news feed in the world

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing

$SYRE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$SYRE Financials

Live finance-specific insights

Wedbush initiated coverage on Spyre Therapeutics with a new price target

Evercore ISI initiated coverage on Spyre Therapeutics

Robert W. Baird initiated coverage on Spyre Therapeutics with a new price target

Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024

$SYRE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Albers Jeffrey W. sold $246,313 worth of shares (6,700 units at $36.76) (SEC Form 4)

Director Albers Jeffrey W. sold $10,929 worth of shares (300 units at $36.43) (SEC Form 4)

SEC Form 4 filed by Chief Medical Officer Sloan Sheldon

$SYRE Large Ownership Changes

This live feed shows all institutional transactions in real time.